MSB 12.1% 55.5¢ mesoblast limited

That is not quite what MSB said - they only announced a DMC...

  1. 693 Posts.
    lightbulb Created with Sketch. 266
    That is not quite what MSB said - they only announced a DMC review of randomised patients, not another futility analysis!

    They have not said anything about the nature of the review, and absent this we can only conclude that it is a routine analysis of the blinded data to see if enough events have occurred overall to ensure the trial has a chance of generating statistically significant results. These reviews are routine, but say nothing about the chances of success or failure.

    And so it's not a pass or fail on the treatment at all, it's saying there are enough events occurring to justify continuation - for example if there were no cardiac events at all in the blinded data you might as well terminate the trial now!

    I'm sure if the review was any more than this routine analysis MSB would have said so!
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
55.5¢
Change
0.060(12.1%)
Mkt cap ! $633.0M
Open High Low Value Volume
50.0¢ 59.0¢ 48.5¢ $16.88M 30.80M

Buyers (Bids)

No. Vol. Price($)
7 99223 55.5¢
 

Sellers (Offers)

Price($) Vol. No.
56.0¢ 44000 4
View Market Depth
Last trade - 16.10pm 28/03/2024 (20 minute delay) ?
Last
55.5¢
  Change
0.060 ( 15.7 %)
Open High Low Volume
50.5¢ 59.0¢ 48.5¢ 11524458
Last updated 16.02pm 28/03/2024 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.